Cancer Cachexia

Global Market Trajectory & Analytics

MCP16251

EXECUTIVE ENGAGEMENTS

POOL

3501
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

632
Interactions with Platform & by Email

PARTICIPANTS

103
Unique # Participated

VALIDATIONS

32
Responses Validated*

COMPANIES

29
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2021

TABLES

99

PAGES

199

EDITION

7

PRICE

USD 4950

CODE

MCP16251


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

S M N T

%

VALIDATED RESEARCH *

S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T

* S = Strong; M = Moderate; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
  

HIGHLIGHTS & REPORT INDEX

Global Cancer Cachexia Market to Reach US$2.8 Billion by the Year 2026

Unintentional weight loss or cachexia, which is a complication associated with cancer, is highly prevalent, affecting over 30 million people and more than 50% to 80% of all cancer patients across the world and potentially leading to increased risk of death or significant functional impairment. Primarily considered a metabolic disorder, cachexia is a comorbidity associated with many chronic diseases such as chronic kidney disease (CKD), cancer, chronic obstructive pulmonary disease (COPD, and heart failure. Cachexia in the case of cancer, called cancer cachexia, is described as the multifactorial syndrome featuring body weight loss, anemia, asthenia and anorexia. The factors however, manifest in variable degrees based on the stage of the disease. Cachexia is associated with elevated Growth Differentiation Factor-15 (GDF-15) in cancer patients, and the range of GDF-15 depends on individual body types, the type of the tumor, and the patient`s response to progression of tumor. Growth in the global market is set to be driven by rising incidence of cancer globally, and increasing R&D funding to develop novel and sophisticated treatment options with certain mode of action. The market growth is favored by increasing attention on palliative cancer care along with rising incidence of cancer. Treatment modalities for cancer cachexia include appetite stimulants and drugs. There are several pipeline drugs in the late stages of clinical trials, for cancer cachexia treatment, which are anticipated to be commercialized over the coming two to three years. This is also expected to drive market growth.

Amid the COVID-19 crisis, the global market for Cancer Cachexia estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$2.8 Billion by 2026, growing at a CAGR of 4.6% over the analysis period. Progestogens, one of the segments analyzed in the report, is projected to grow at a 4.7% CAGR to reach US$1.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 4.1% CAGR for the next 7-year period. This segment currently accounts for a 24.7% share of the global Cancer Cachexia market. Progestogens represent the largest segment, due to the low cost, safety and effectiveness. Progestogens improve appetite and aid in weight gain. Corticosteroids are generally used by medical professionals for stimulating appetite. Researchers have investigated oral dexamethasone in randomized trials involving cancer patients. These trials indicated the potential of the drug to improve appetite and non-fluid weight gain.

The U.S. Market is Estimated at $879.7 Million in 2021, While China is Forecast to Reach $232.6 Million by 2026

The Cancer Cachexia market in the U.S. is estimated at US$879.7 Million in the year 2021. The country currently accounts for a 40.07% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$232.6 Million in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$250.2 Million by the end of the analysis period. Presence of several major drug manufacturers in the region coupled with the factor of increasing number of cancer patients and need for care for the patients promotes dominance of North America region. Market growth in Asia-Pacific region is due to growing geriatric population and increasing awareness about supportive care for cancer patients both among healthcare professionals and patients.

Combination Therapies Segment to Reach $639.7 Million by 2026

Recent therapy developments in the treatment of cancer cachexia have been combination therapies, supplemented with exercise routines and modification in diets. Pharmaceutical agents like medroxyprogesterone and megestrol among others are being used along with exercise and diet for improving survival rates and quality for life. In the global Combination Therapies segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$396.7 Million in the year 2020 will reach a projected size of US$576.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$48.4 Million by the year 2026.

SELECT PLAYERS

AstraZeneca plc; AVEO Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH.; Eli Lilly and Company; Helsinn Healthcare SA; INOVIO Pharmaceuticals; Marsala Biotech Inc.; MetaFines Co., Ltd.

SEGMENTS

» Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics) » End-Use (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Cancer - An Insight
A Prelude to Cancer Cachexia
Cachexia Treatment
Pharmacologic Approaches for Clinical Management of Cancer Cachexia
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
Impact of COVID-19 on Cancer Cachexia Market
Global Market Prospects and Outlook
Global Cancer Cachexia Market Set for a Rapid Growth
Progestogens Accounts for a Major Share, Combination Therapies to Drive Growth
North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
Competition
Recent Market Activity
Based on Mechanism of Action
Market Challenges
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
EXHIBIT: Breakdown of Total Number of Cancer Cases by Region: 2020
EXHIBIT: Breakdown of Total Number of Cancer Cases by Type: 2020
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Ageing Demographics to Drive Market Demand
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Uptrend in Healthcare Spending Drives Market Demand
EXHIBIT 2: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
Cancer Research Spending Continues to Witness Growth
Number of FDA-Approved Cancer Drugs: 2010-2018
Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
Pipeline Analysis
Macimorelin from AEterna Zentaris
PF- 06946860 from Pfizer
TCMCB07 from Endevica Bio
Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
Promising but yet to be Approved Treatment Options Drive Market Gains
NSAID
Erythropoietin
IL-1α, IL-6 & TNFα Inhibitors
Myostatin Inhibitors
Appetite & Metabolism Modulators
New Potential Therapeutic Options
Select Key Developments
Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Current & Future Analysis for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Progestogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
UNITED STATES
USA Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
USA Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CANADA
Canada Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Canada Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
JAPAN
Japan Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Japan Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CHINA
China Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
China Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
EUROPE
Europe Current & Future Analysis for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Europe Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
FRANCE
France Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
France Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
GERMANY
Germany Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Germany Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ITALY
Italy Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Italy Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
UK Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Rest of Europe Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Asia-Pacific Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
Rest of World Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
Total Companies Profiled: 29

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com